BREAKING COVID-19 News! Studies Show That BA.2.86 And JN.1 Targets The Lungs More Effectively And Has Enhanced Cell Fusion Capabilities!

COVID-19 News: The relentless evolution of the SARS-CoV-2 virus continues to unveil new challenges in the global fight against COVID-19. Two recent groundbreaking studies published in the prestigious journal Cell have shed light on the BA.2.86 and JN.1 variants, introducing a complex layer of mutations that may have profound implications for the severity of the disease. As the world grapples with the evolving nature of the pandemic, these variants have become focal points of concern and scientific scrutiny.


The BA.2.86 Variant And Its Spawn JN.1 Targets The Lungs More effectively And Has
Enhanced Cell Fusion Capailibities, Hence Driving Disease Severity.
 
Two new studies show that BA.2.86 and its various sub-lineages including BA.2.86 are not only targeting the lungs more effectively but also has enhanced cell-fusion capability and are likely to be driving disease severity. These new findings contradict statements made by made health officials, many who have no relevant medical training, late last year when they claimed that BA.2.86 and JN.1 does not cause disease severity despite rising hospitalizations and ICU admissions and overwhelmed ER departments!
 
BA.2.86: A Formidable Adversary Emerges
At the forefront of this unfolding narrative is BA.2.86, a highly mutated subvariant of the Omicron strain. Researchers at Ohio State University embarked on a series of experiments, utilizing a BA.2.86 pseudovirus - a non-infectious laboratory-created version designed for controlled investigations. The results of these experiments have unearthed alarming efficiency in BA.2.86's ability to fuse with human cells, particularly those lining the lower lungs.
https://www.cell.com/cell/fulltext/S0092-8674(23)01400-9
 
The Ohio State study, led by Dr Shan-Lu Liu, a prominent virology professor, has raised concerns that BA.2.86 may exhibit characteristics reminiscent of earlier, more lethal SARS-CoV-2 lineages. The variant's enhanced ability to infect cells in the lower lung raises the specter of increased severity in disease outcomes, challenging the initial perception that Omicron variants tend to cause milder illness.
 
Global Confirmation and Escalating Hospitalizations
Parallel research conducted in Germany and France has corroborated the findings from Ohio State University. The authors of this study echoed the conclusion that BA.2.86 has indeed regained traits characteristic of early SARS-CoV-2 lineages, particularly robust lung cell entry. This convergence of evidence paints a concerning picture, suggesting that BA.2.86 might pose an elevated health threat compared to its Omicron predecessors.
https://www.cell.com/cell/pdf/S0092-8674(23)01399-5.pdf
 
Dr Liu emphasizes that the evidence surrounding BA.2.86 cannot be ignored, especially in light of the escalating COVID-19 hospitalizations observed both in the United States and globally. The initial perception of Omicron causing milder illness may be in flux, and the scientific community is grappli ng with the implications of this potential shift in disease severity.
 
Rise Of Severe Pneumonia, ARDs And Increased In Disease Severity As Seen In Increased Hospitalizations, ICU Admissions And Overwhelmed ER Departments Globally.
 
The study findings were corroborated by what was seen in the last few weeks and also currently, where not only are COVID-19 cases increasing exponentially, but COVID-19 hospitalizations, ICU admissions and ER departments across various countries are simply rising at exponential rates. These has been reported by various COVID-19 News coverages.
 
Governments around the world that are controlled by the WEF have been instructed to downplay or conceal the actual impact of the ongoing crisis triggered by the BA.286 variant and its sub-lineages like JN.1.
https://twitter.com/ThailandMedicaX/status/1734580738778157230
 
We can expect later revelations months down the road or even years to reveal that excess mortality rates during this JN.1 wave were phenomenal.
 
Thailand Medical News would like also like to warn as what we have been posting continuously on twitter (Now known as X), we are also witnessing high amounts of individuals developing what is termed as ‘accelerated lung fibrosis’ and even lung carcinoma merely days or weeks after infection. This is something that warrants urgent research and validation.
 
https://twitter.com/ThailandMedicaX/status/1739269036767420741
 
https://twitter.com/ThailandMedicaX/status/1734400040897319038
 
https://twitter.com/ThailandMedicaX/status/1731120300203635083
 
https://twitter.com/ThailandMedicaX/status/1741742713031311487
 
https://twitter.com/ThailandMedicaX/status/1744237113833562247
 
Unraveling the Omicron Enigma - Shifting Disease Dynamics
The narrative surrounding Omicron has been marked by its tendency to cause milder illness compared to earlier variants. However, experts caution that this perception may be influenced by factors such as prior infections and vaccinations. BA.2.86 and its potential for increased severity underscore the dynamic nature of the virus and the need for continuous surveillance to adapt strategies in response to an evolving threat.
 
Dr Liu, the lead author of the Ohio State study, emphasizes that the evolving nature of Omicron, especially through its BA.2.86 subvariant, demands attention. The increasing COVID-19 hospitalizations serve as a stark reminder that the virus is not static, and its potential to cause severe disease remains a significant concern.
 
Navigating Waning Immunity - The Crucial Role of Boosters
Amid the uncertainty surrounding the potential shift in disease severity, the dynamics of waning immunity add another layer of complexity to the evolving threat. Antibody immunity to COVID-19, whether from vaccination or prior infection, tends to decline after three to six months. Globally, the uptake of the latest COVID booster, released in the fall, has been less than optimal, with the U.S. reporting booster coverage under 20%, according to the U.S. Centers for Disease Control and Prevention.
 
The temporal aspect of immunity amplifies the risk of severe outcomes, such as hospitalization and death, for those with waning immunity. The urgency for timely booster shots becomes evident, especially in the face of BA.2.86's potential to cause more severe disease. The ongoing challenge lies in ensuring widespread booster coverage to mitigate the risks posed by these emerging variants.
 
JN.1 - A Gastrointestinal Dimension to the Puzzle
As BA.2.86 takes the spotlight, its descendant, JN.1, adds a new layer of complexity to the narrative. Preliminary indications from expert speculation suggest that JN.1 may exhibit a preference for infecting the gastrointestinal (GI) tract. This revelation adds another intriguing dimension to the evolving nature of the virus, raising questions about its varied impact on different organ systems.
https://twitter.com/ThailandMedicaX/status/1735261590549930271
 
Dr Liu's concern extends beyond the immediate threat posed by BA.2.86 and JN.1. He emphasizes the potential for COVID to recombine with another coronavirus in animals, creating a scenario where the virus transitions back to humans. The unpredictable role of animals, exemplified by white-tailed deer in Ohio testing positive for COVID, underscores the need for ongoing surveillance and the recognition of animals as potential reservoirs for viral evolution.
 
Vaccine Effectiveness - Navigating the Balance
Despite the concerning characteristics of BA.2.86, recent research offers a silver lining regarding vaccine effectiveness. The studies claim that bivalent mRNA vaccine-induced antibodies can neutralize BA.2.86 in the blood, providing a plausible explanation for why the variant did not cause a widespread surge as initially feared.
 
However, the efficiency of neutralization is notably reduced compared to other Omicron variants. Dr Liu emphasizes the importance of acknowledging that natural infection alone does not provide sufficient immunity, especially considering the lower virulence of Omicron variants. The key lies in embracing the latest booster vaccines, specifically formulated to combat BA.2.86 and its sub-lineages.
 
S309 Antibody Conundrum - A Molecular Puzzle Unfolds
A surprising revelation in the Ohio research is the S309 monoclonal antibody, renowned for its efficacy against almost all major Omicron variants, failing to neutralize BA.2.86. Molecular modeling suggests that mutations in the BA.2.86 spike protein might have altered its conformation, rendering S309 ineffective against this new variant.
 
The molecular puzzle surrounding BA.2.86 deepens as additional experiments indicate the variant's increased efficiency in infecting human lung cells, particularly those lining the lower airway. The involvement of the TMPRSS2 cell surface protein, known to contribute to SARS-CoV-2 infection and respiratory disease symptoms, adds a layer of complexity to the variant's pathogenic potential.
 
Global Spread and Ongoing Surveillance - A Call to Collective Action
As BA.2.86 and its sub-lineages, including JN.1, continue to spread globally, the studies underscore the paramount importance of ongoing surveillance. The threat of viral recombination, the uncertain role of animals, and the potential merging of more deadly coronaviruses like SARS or MERS with COVID add layers of complexity to the future of the pandemic.
 
Dr Liu remains steadfast in emphasizing the need for vigilance and continued monitoring of variants. The evolving nature of coronaviruses, coupled with their propensity for recombination, underscores the importance of staying proactive in the face of an ever-changing viral landscape. The collective action of the global community is imperative to understand, adapt, and overcome the evolving threat of the virus.
 
Conclusion- Navigating the Uncertain Path Ahead
In conclusion, the breaking news on BA.2.86 and JN.1 variants raises significant concerns about the evolving threat of COVID-19. The studies indicate a potential shift towards more severe disease, challenging previous perceptions of Omicron's milder impact. As the world grapples with these new challenges, the emphasis on vaccination, timely boosters, and vigilant surveillance remains crucial in navigating the uncertain path ahead.
 
The evolving landscape of COVID-19 demands a proactive and adaptable approach to mitigate the risks posed by these emerging variants. As we delve deeper into the intricacies of BA.2.86 and JN.1, the global community must unite in a concerted effort to understand, adapt, and overcome the evolving threat of the virus. The future of the pandemic hinges on our collective ability to stay ahead of the mutating virus and protect the well-being of communities worldwide.
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.
 
Read Also:
 
https://twitter.com/ThailandMedicaX/status/1731678715719856228
 
https://twitter.com/ThailandMedicaX/status/1733299581000282608